From 406 Days to 240: What Is Changing in Korea's Bio-Drug Approvals
In 2026, Korea's Ministry of Food and Drug Safety (MFDS) officially announced its goal to reduce bio-drug approval timelines to 240 days or fewer. This represents a dramatic improvement from the 406-day average recorded just a few years ago.
Behind this acceleration are the Four Key K-Bio Regulatory Innovation Measures: strengthened pre-submission consultations, parallel review tracks, an upgraded digital submission system, and global regulatory harmonization.
Three Institutional Changes Enabling Faster Approvals
1. Formalized Pre-Approval GMP Assessment
A pre-approval GMP assessment procedure has been formally established, enabling GMP inspection and dossier review to run in parallel.
2. Parallel Review of Approval Dossiers
The traditional sequential review is being replaced by simultaneous parallel review.
3. Digital Submission and Communication Upgrades
eCTD submission is now mandatory, with a real-time online communication platform replacing paper correspondence.
Essential Strategies for SME Biotech Companies
KITIM provides end-to-end support for SME biotech companies navigating fast-track approvals. Contact KITIM today.